Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05284019 · ClinicalTrials.gov registry record · Phase 4
Real World Effectiveness of Eptinezumab in Participants With Migraine
A Phase 4 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05284019: Clinical Trial Phase 4 study, sponsored by H. Lundbeck A/S.
NCT05284019 is a Phase 4 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 32 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05284019, a Phase 4 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.
Primary Outcome
Participants select the symptom that they find most impairs them at the time of reporting and rate the severity of that symptom on a 7-point scale (1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse) where a high score indicated worsening. Score ranges from 1 (Very Much Improved) to 7 (Very Much Worse). Lower scores indicate better health status. The MBS areas included: nausea, vomiting, sensitivity to light,
Interventions
- DRUG Eptinezumab
- DRUG Galcanezumab
- DRUG Fremanezumab
- DRUG Erenumab
- DRUG Onabotulinumtoxin-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 4 |
Why NCT05284019 stopped before completion
NCT05284019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Eptinezumab is the first listed.
NCT05284019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05284019 about?
NCT05284019 is a clinical study titled "Real World Effectiveness of Eptinezumab in Participants With Migraine". The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported...
What is the current status of trial NCT05284019?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2022-03-04. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT05284019?
The interventions under investigation include: Eptinezumab (DRUG), Galcanezumab (DRUG), Fremanezumab (DRUG), Erenumab (DRUG), Onabotulinumtoxin-A (DRUG).
Who is sponsoring clinical trial NCT05284019?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05284019's enrollment target sits among peer trials
32 1534th of 2000 higher than 457 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI